Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

China Growth Capital

Founders Haiyan Wu Ning Tang

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 210
Average round size
info
The average size of a deal this fund participated in
$13M
Portfolio companies 165
Rounds per year 11.67
Lead investments 57
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 13
Key employees 5
Stages of investment
Early Stage Venture
Seed

Areas of investment

  • Information Technology
  • Software
  • E-Commerce
  • Financial Services
  • Internet
Summary

China Growth Capital is the famous VC, which was founded in 2006. The main department of described VC is located in the Beijing. The fund was located in Asia if to be more exact in China.

The fund was created by Ning Tang. Besides them, we counted 5 critical employees of this fund in our database.

Comparing to the other companies, this China Growth Capital performs on 25 percentage points less the average number of lead investments. The higher amount of exits for fund were in 2019. When the investment is from China Growth Capital the average startup value is 100-500 millions dollars. The fund is generally included in 7-12 deals every year. The high activity for fund was in 2018. Speaking about the real fund results, this VC is 14 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars.

The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the China Growth Capital, startups are often financed by Matrix Partners China, Yunqi Partners, The Hina Group. The meaningful sponsors for the fund in investment in the same round are Matrix Partners China, Qiming Venture Partners, Shunwei Capital. In the next rounds fund is usually obtained by Sequoia Capital China, Linear Venture, Welight Capital.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. The fund has no exact preference in some founders of portfolio startups. We can highlight the next thriving fund investment areas, such as Mobile, Information Technology. Among the most popular portfolio startups of the fund, we may highlight MissFresh E-Commerce, Klook, Tongdun Technology.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of China Growth Capital:
Typical Co-investors
China Growth Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after China Growth Capital:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Hangke New Materials

Advanced Materials
Manufacturing
18 Dec 2023 Shenzhen, Guangdong, China

Xinsheng Semiconductor

Electronics
Manufacturing
Semiconductor
$46M28 Feb 2023 Futian, Guangdong, China

Immorna

Biotechnology
Health Care
Medical
$13M27 Feb 2023 Hangzhou, Zhejiang, China

Better Medtech

Health Care
Hospital
Medical
20 Oct 2022 Jiading, Shanghai, China

Well-link

$40M26 Sep 2022 -

Gongda Laser

Hardware
Industrial Manufacturing
Laser
Manufacturing
$15M04 Jul 2022 Shenzhen, Guangdong, China

Dewy Lab

Beauty
Cosmetics
22 Feb 2022 Huangpu, Shanghai, China

Apifox

Enterprise Applications
Software
Software Engineering
$4M05 Jan 2022 Guangzhou, Guangdong, China

Innogen Pharmaceutical

Biopharma
Biotechnology
Pharmaceutical
$120M23 Dec 2021 Shanghai, Shanghai, China

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent China Growth Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 210
Average round size 13M
Rounds per year 11.67
Peak activity year 2018
Lead investments 57
Follow on index 0.20
Exits 13
Group Appearance index 0.76

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Hangke New Materials

Advanced Materials
Manufacturing
18 Dec 2023 Shenzhen, Guangdong, China

Xinsheng Semiconductor

Electronics
Manufacturing
Semiconductor
$46M28 Feb 2023 Futian, Guangdong, China

Immorna

Biotechnology
Health Care
Medical
$13M27 Feb 2023 Hangzhou, Zhejiang, China

Better Medtech

Health Care
Hospital
Medical
20 Oct 2022 Jiading, Shanghai, China

Well-link

$40M26 Sep 2022 -

Gongda Laser

Hardware
Industrial Manufacturing
Laser
Manufacturing
$15M04 Jul 2022 Shenzhen, Guangdong, China

Dewy Lab

Beauty
Cosmetics
22 Feb 2022 Huangpu, Shanghai, China

Apifox

Enterprise Applications
Software
Software Engineering
$4M05 Jan 2022 Guangzhou, Guangdong, China

Innogen Pharmaceutical

Biopharma
Biotechnology
Pharmaceutical
$120M23 Dec 2021 Shanghai, Shanghai, China
Crunchbase icon

Content report

The following text will be sent to our editors: